SABCS Snippets: Results of the COMET Study (AFT-25)

(7:25)

SABCS Snippets: Risk-Reducing Surgeries and Survival in Young BRCA Carriers

(6:)

SABCS Snippets: Results from the OlympiA Trial

(7:8)

SABCS Snippets: The US FDA Approval of Ribociclib

(5:32)

SABCS Snippets: Mammographic surveillance in early breast cancer patients over 50

(2:46)

SABCS Snippets: Results from the AFT-38 PATINA Trial

(7:16)

SABCS Snippets: Results of the EMBER-3 Trial

(6:6)

SABCS Snippets: The Critical Value of Career Development Programs for Women in STEM

(4:22)

SABCS Snippets: Results from the Breast Cancer Weight Loss (BWEL) Trial

(5:7)

State of the Art: Implications of Senescence for Breast Cancer Biology and Treatment

(1:6:24)

Year in Review

(2:7:56)

2021 SABCS What Changes Monday Morning? Triple-Negative Breast Cancer Panel Discussion

(1:28:8)

SABCS Snippets: KEYNOTE-522 Phase 3 Results

(11:45)

Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)

(1:2:6)

SABCS Clinical Case Discussions

(57:53)

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal

(51:40)

2021 SABCS What Changes Monday Morning? HER2+ Breast Cancer Panel Discussion

(1:29:7)

Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results - SABCS - Otto Metzger, MD

(14:38)

SABCS Snippets: DESTINY-Breast06 Phase III Trial

(4:22)

SABCS Snippets: Magnetic Resonance Imaging and a 12-Gene Expression Assay

(5:55)

SABCS Snippets: SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer

(5:30)

SABCS Snippets: McGuire Memorial Lecture Award Recipient Laura J. van 't Veer, PhD

(6:4)

SABCS Snippets: Five-year outcomes of the IDEA trial

(5:38)

SABCS Snippets: Artificial Intelligence in the Clinic

(6:2)

SABCS Snippets: Fertility preservation and assisted reproductive technologies

(5:57)

SABCS Snippets: The multinational randomized controlled PREFERABLE-EFFECT study

(5:13)

SABCS Snippets: After ASCO 2024

(20:17)

SABCS Snippets: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial

(5:56)